ResMed (RMD)

Equity
Sell: $221.36|Buy: $236.59|Change: 1.15 (-0.48%)

Open 

$236.29


Previous close 

$237.74


Trade high 

$237.40


Volume 

1,320,376


Year high 

$263.05


Year low 

$179.42


Dividend yield 

0.87%


Market capitalisation 

$34.69 bn


P/E ratio 

26.68


ISIN 

US7611521078


Share price

Dividends

PreviousLatest
Record date13/02/202508/05/2025
Ex-dividend date13/02/202508/05/2025
Payment date20/03/202512/06/2025
Amount$0.53$0.53

Performance 29/04/2025

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann


Total return (%)
ResMed+ 1.54
More...

Company profile

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.

Sector 

Healthcare


AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2025 AJ Bell. All rights reserved.